ECSP003719A - USE OF DIPIRIDAMOL OR MOPIDAMOL FOR THE TREATMENT AND PREVENTION OF FIBRINE DEPENDENT MICROCIRCULATION DISORDERS - Google Patents
USE OF DIPIRIDAMOL OR MOPIDAMOL FOR THE TREATMENT AND PREVENTION OF FIBRINE DEPENDENT MICROCIRCULATION DISORDERSInfo
- Publication number
- ECSP003719A ECSP003719A ECSP003719A ECSP003719A EC SP003719 A ECSP003719 A EC SP003719A EC SP003719 A ECSP003719 A EC SP003719A EC SP003719 A ECSP003719 A EC SP003719A
- Authority
- EC
- Ecuador
- Prior art keywords
- microcirculation disorders
- mopidamol
- human
- treatment
- dipiridamol
- Prior art date
Links
- 230000004089 microcirculation Effects 0.000 title abstract 5
- 230000001419 dependent effect Effects 0.000 title abstract 2
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 title abstract 2
- FOYWNSCCNCUEPU-UHFFFAOYSA-N mopidamol Chemical compound C12=NC(N(CCO)CCO)=NC=C2N=C(N(CCO)CCO)N=C1N1CCCCC1 FOYWNSCCNCUEPU-UHFFFAOYSA-N 0.000 title abstract 2
- 229950010718 mopidamol Drugs 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 208000035475 disorder Diseases 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 2
- JOZPEVMCAKXSEY-UHFFFAOYSA-N pyrimido[5,4-d]pyrimidine Chemical compound N1=CN=CC2=NC=NC=C21 JOZPEVMCAKXSEY-UHFFFAOYSA-N 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 102000009123 Fibrin Human genes 0.000 abstract 1
- 108010073385 Fibrin Proteins 0.000 abstract 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 229960002768 dipyridamole Drugs 0.000 abstract 1
- 229950003499 fibrin Drugs 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000013467 fragmentation Methods 0.000 abstract 1
- 238000006062 fragmentation reaction Methods 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000003836 peripheral circulation Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se describe un método de tratamiento de un cuerpo animal humano o no humano, para tratar o prevenir trastornos de la microcirculación dependientes de fibrina, por ejemplo trastornos de la microcirculación provocados por enfermedades metabólicas, reacciones inflamatorias o enfermedades autoinmunes, y además trastornos de la microcirculación periférica o trastornos de la microcirculación asociados con una fragmentación celular incrementada, tal método comprende administrar a un cuerpo animal humano o no humano, que necesite tal tratamiento una cantidad eficaz de una composición farmacéutica que contiene una pirimido-pirimidina seleccionada de dipiridamol, mopidamol y las sales farmacéuticamente aceptables de los mismos, y el uso de dicha pirimido-pirimidina para la fabricación de una formulación farmacéuticamente correspondiente.A method of treating a human or non-human animal body is described to treat or prevent fibrin-dependent microcirculation disorders, for example microcirculation disorders caused by metabolic diseases, inflammatory reactions or autoimmune diseases, and also microcirculation disorders. peripheral or microcirculation disorders associated with increased cell fragmentation, such a method comprises administering to an human or non-human animal body, such treatment needs an effective amount of a pharmaceutical composition containing a pyrimido-pyrimidine selected from dipyridamole, mopidamol and the pharmaceutically acceptable salts thereof, and the use of said pyrimido-pyrimidine for the manufacture of a pharmaceutically corresponding formulation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP003719 ECSP003719A (en) | 2000-10-17 | 2000-10-17 | USE OF DIPIRIDAMOL OR MOPIDAMOL FOR THE TREATMENT AND PREVENTION OF FIBRINE DEPENDENT MICROCIRCULATION DISORDERS |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP003719 ECSP003719A (en) | 2000-10-17 | 2000-10-17 | USE OF DIPIRIDAMOL OR MOPIDAMOL FOR THE TREATMENT AND PREVENTION OF FIBRINE DEPENDENT MICROCIRCULATION DISORDERS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP003719A true ECSP003719A (en) | 2001-05-23 |
Family
ID=42041299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP003719 ECSP003719A (en) | 2000-10-17 | 2000-10-17 | USE OF DIPIRIDAMOL OR MOPIDAMOL FOR THE TREATMENT AND PREVENTION OF FIBRINE DEPENDENT MICROCIRCULATION DISORDERS |
Country Status (1)
| Country | Link |
|---|---|
| EC (1) | ECSP003719A (en) |
-
2000
- 2000-10-17 EC ECSP003719 patent/ECSP003719A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR026197A1 (en) | USE OF DIPIRIDAMOL OR MOPIDAMOL FOR THE TREATMENT AND PREVENTION OF FIBRINE DEPENDENT MICROCIRCULATION DISORDERS | |
| PA8606201A1 (en) | PIRROLO DERIVATIVES [3,4-c) PIRAZOL ASSETS AS QUINASE INHIBITORS, PROCESS FOR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM | |
| AR044007A1 (en) | METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE | |
| BR0313371A (en) | Compound, use of a compound and disease treatment method | |
| MX9703621A (en) | NEW AMINO ACID DERIVATIVES WITH IMPROVED ACTIVITY FOR RESISTANCE TO MULTIPLE DRUGS. | |
| BR9406363A (en) | Pharmaceutical composition process for the preparation of the same use and process for the treatment of diseases related to gastric acid | |
| AR037490A1 (en) | SOLID PHARMACEUTICAL COMPOSITIONS, PROCESS FOR PREPARATION, KIT FOR THE TREATMENT OF OBESITY AND USE OF SUCH COMPOSITIONS IN THE DEVELOPMENT OF MEDICINES | |
| BR0114799A (en) | Cyanophenoxy carboxylic acid compounds and compositions for releasing active agents | |
| AR032293A1 (en) | PHARMACEUTICAL CASE | |
| NO20024646L (en) | Combination therapies with vasculature-damaging activity | |
| BR0311414A (en) | Therapeutic agent for an overactive bladder | |
| BR0306732A (en) | Combination treatments for allergic disease comprising administering an anti-ige antibody and antiallergic compound | |
| PA8525801A1 (en) | PIRAZOL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS TO MODULATE AND / OR INHIBIT THE ACTIVITY OF ERAB / HADH2 | |
| BR0312123A (en) | Nonpeptide Gnrh Agents, Pharmaceutical Compositions and Methods for Their Use | |
| AR032553A1 (en) | DERIVATIVES OF ALFA-AMINO-N-HYDROXI-ACETAMIDE. | |
| ES2125356T3 (en) | USE OF LEFLUNOMIDE FOR INTERLEUKIN INHIBITION 8. | |
| BRPI0408500A (en) | Type 1 diabetes treatment with pde5 inhibitors | |
| MX9403032A (en) | QUINOLYL-DIHYDROPYRIDINES, CONDENSED, PROCEDURE FOR ITS MANUFACTURE AND ITS USE IN MEDICINES. | |
| ECSP003719A (en) | USE OF DIPIRIDAMOL OR MOPIDAMOL FOR THE TREATMENT AND PREVENTION OF FIBRINE DEPENDENT MICROCIRCULATION DISORDERS | |
| BRPI0409790A (en) | 7-azaindoles and their use as therapeutics | |
| CR8584A (en) | PIPERAZINAS DERIVED FROM UREA FOR THE TREATMENT OF ENDOMETROSIS | |
| UY26408A1 (en) | USE OF DIPIRIDAMOL OR MOPIDAMOL FOR THE TREATMENT AND PREVENTION OF FIBRIN DEPENDENT MICROCIRCULATION DISORDERS | |
| HRPK20040328B3 (en) | Pharmaceutical composition comprising gamma-butyrobetaine | |
| WO2002085368A3 (en) | Use of radical scavenging compounds for treatment and prevention of no-dependent microcirculation disorders | |
| AR030660A1 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF AN ILLNESS ASSOCIATED WITH AN EXCESS OF IL-12 PRODUCTION |